Results 161 to 170 of about 2,243,647 (283)

Exceptional Locoregional Pathological Response in Metastatic Triple‐Negative Breast Cancer Treated With Palliative Platinum‐Based Chemotherapy

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT Locoregional pathological complete response with concurrent radiologic metabolic remission following palliative gemcitabine–carboplatin chemotherapy in young, low‐grade metastatic triple‐negative breast cancer patient suggests potential chemosensitivity in select advanced cases, warranting further clinical investigation.
Shristi Gupta, Abhisek Jha, Asmita Rayamajhi, Aron Neupane, Kshitiz Parajuli, Manash Jha   +5 more
wiley   +1 more source

CLDN18.2 in pancreatic ductal adenocarcinoma: Biomarker assessment, spatial heterogeneity and therapeutic modality selection

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
This review presents a framework for selecting Claudin 18.2 (CLDN18.2)‐directed treatment modalities in pancreatic ductal adenocarcinoma according to tumour antigen coverage and spatial distribution. Representative assessment at baseline and reassessment after progression can guide treatment adaptation over time.
Ruyu Tan, Zhexin Zhang, Jiaxin Wang, Roland Andersson, Daniel Ansari, Jinfei Chen   +5 more
wiley   +1 more source

Systemic Treatments for Recurrent or Metastatic Sinonasal Carcinomas: A Retrospective Multicenter Study

Head &Neck, Volume 48, Issue 10, Page 2810-2820, October 2026.
ABSTRACT Introduction Sinonasal cancers are rare and heterogeneous and pose a therapeutic challenge at an advanced stage due to the lack of data on appropriate systemic management. Methods This retrospective multicenter study analyzed 83 patients with recurrent or metastatic sinonasal carcinomas ineligible for curative treatment, treated in France ...
Marie Degrange, Mathilde Morisseau, Justin Michel, Thibaut Reverdy, Sylvain Morinière, Amaury Daste, Maxime Humbert, Caroline Viala, Pauline Corbaux, Tiffany Darbas, François‐Régis Ferrand, Valentin Favier, Camille Evrard, Diane Evrard, Delphine Farneti, Sarah Betrian‐Lagarde, Victor Sarradin   +16 more
wiley   +1 more source

MGLL Coordinates YWHAZ to Mediate Gemcitabine Resistance in Pancreatic Cancer via IL6/PI3K/AKT Signaling Pathway

Background: The frequency of neoplastic disorders, pancreatic ductal adenocarcinoma (PDAC), is increasing annually. PDAC is an aggressive cancer and can be partly managed with systemic chemotherapy, as it is usually diagnosed at advanced stages ...
Bian, Jinda, Zhou, Shuai, Luo, Qiankun, Qin, Tao, Zhang, Xu, Yu, Pengfei, Liu, Pan, Fu, Qiang, Zhang, Qing, Zhang, Hongwei, Wei, Jinli   +10 more
core   +1 more source

Ellagic Acid Enhances RSL3‐Induced Ferroptosis by Inhibiting the Nrf2/HO‐1 Signaling Pathway in Pancreatic Ductal Adenocarcinoma

The FASEB Journal, Volume 40, Issue 18, 30 September 2026.
Ellagic acid potentiates RSL3‐induced ferroptosis in PANC‐1 by suppressing the Nrf2/HO‐1 antioxidant defense axis via p38 MAPK activation and Keap1 upregulation. In PDAC cells, constitutive Nrf2/HO‐1 signaling establishes a robust antioxidant shield (GPX4, HO‐1) that limits lipid ROS accumulation and confers ferroptosis resistance.
Jianhua Bai, Yihe Dai, Chern Ein Oon, Pingping Hu, Jia Luo, Jiang Han, Liman Yang, Amirabas Bostani, Zhenhao Fei, Yun Jin   +9 more
wiley   +1 more source

Membrane and soluble VTCN1 (B7H4) converge on Src signaling to mediate gemcitabine resistance in intrahepatic cholangiocarcinoma. [PDF]

Theranostics
Pan YR, Lin SH, Chang YC, Jung SM, Wu CE, Huang WK, Yeh CN.   +6 more
europepmc   +1 more source

Unveiling the Diagnostic Value and Potential Therapeutic Targets of Phenylalanine Metabolism in Pancreatic Cancer via Integrated Multi‐Omics and Machine Learning

The FASEB Journal, Volume 40, Issue 18, 30 September 2026.
MR identified phenylalanine as a causal PC risk factor (OR 1.18). A 5‐gene RF model (AUC 0.955) highlighted SLC6A14 as the top biomarker. Single‐cell analysis revealed epithelial–immune crosstalk. Molecular docking identified genistein (−9.1 kcal/mol) as a lead SLC6A14‐targeting compound.
Xing Liu, Yibin Li, Fangfang Qin, Jianghong Ou   +3 more
wiley   +1 more source

The evolving role of immunotherapy in ovarian cancer

Cancer, Volume 132, Issue 18, 15 September 2026.
Abstract Ovarian cancer remains a major cause of gynecologic cancer mortality; and, although immune checkpoint inhibitors have transformed treatment in other solid tumors, their activity in ovarian cancer has been limited by tumor heterogeneity, an immunosuppressive tumor microenvironment, and the lack of robust predictive biomarkers.
Ana Carolina Veneziani, Laura Venegas, Amit M. Oza   +2 more
wiley   +1 more source

Tumor B‐cell infiltration in platinum‐treated advanced muscle‐invasive urothelial carcinoma

Molecular Oncology, Volume 20, Issue 9, Page 2340-2355, September 2026.
Bladder tumors with higher pretreatment memory B‐cell infiltration were linked to longer survival after cisplatin chemotherapy, but not carboplatin. These tumors also showed more organized immune structures (tertiary lymphoid structures) and a shared pro‐inflammatory B‐cell‐rich community, suggesting that memory B cells may help identify patients most ...
Konrad Stawiski, Júlia Perera‐Bel, Alejo Rodriguez‐Vida, Nuria Juanpere, Jihyun Lee, Daniel E. Michaud, Jennifer L. Guerriero, Kent W. Mouw, Aristotelis Bamias, Filipe L. F. Carvalho, Joaquim Bellmunt   +10 more
wiley   +1 more source

From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer. [PDF]

Front Immunol
Jin M, Cai Z, Bu M, Liu J, Zhang X.
europepmc   +1 more source